A Randomized, Parallel-group, Placebo-controlled, Double-blind Phase 1 Study in Healthy HIV-uninfected Adults to Evaluate Safety/Tolerability and Immunogenicity of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C gp140
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Jun 2017
At a glance
- Drugs Ad26 Mos HIV (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Janssen Infectious Diseases BVBA; Janssen Vaccines and Prevention
- 20 Jun 2017 Planned End Date changed from 1 Jan 2018 to 15 Jan 2018.
- 10 Jun 2017 Biomarkers information updated
- 26 Oct 2016 Status changed from recruiting to active, no longer recruiting.